Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 135 points (0.8%) at 17,576 as of Tuesday, July 28, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,150 issues advancing vs. 862 declining with 147 unchanged.

The Drugs industry currently sits up 1.2% versus the S&P 500, which is up 0.9%. Top gainers within the industry include

Amgen

(

AMGN

), up 4.1%,

Alexion Pharmaceuticals

(

ALXN

), up 2.6%,

Regeneron Pharmaceuticals

(

REGN

), up 2.4%,

Celgene

(

CELG

), up 2.1% and

Vertex Pharmaceuticals

(

VRTX

), up 2.1%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Johnson & Johnson

(

JNJ

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Johnson & Johnson is up $0.58 (0.6%) to $98.86 on light volume. Thus far, 2.6 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 7.4 million shares. The stock has ranged in price between $98.42-$98.93 after having opened the day at $98.89 as compared to the previous trading day's close of $98.28.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. Johnson & Johnson has a market cap of $274.9 billion and is part of the health care sector. Shares are down 6.0% year-to-date as of the close of trading on Monday. Currently there are 8 analysts who rate Johnson & Johnson a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Johnson & Johnson

as a

buy

. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Johnson & Johnson Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Pfizer

(

PFE

) is up $0.65 (1.9%) to $34.99 on average volume. Thus far, 11.3 million shares of Pfizer exchanged hands as compared to its average daily volume of 22.7 million shares. The stock has ranged in price between $34.40-$34.99 after having opened the day at $34.94 as compared to the previous trading day's close of $34.34.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Pfizer has a market cap of $211.0 billion and is part of the health care sector. Shares are up 10.2% year-to-date as of the close of trading on Monday. Currently there are 8 analysts who rate Pfizer a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Pfizer

as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and growth in earnings per share. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Pfizer Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Gilead

(

GILD

) is up $1.85 (1.7%) to $112.39 on average volume. Thus far, 6.6 million shares of Gilead exchanged hands as compared to its average daily volume of 10.8 million shares. The stock has ranged in price between $110.74-$112.95 after having opened the day at $112.52 as compared to the previous trading day's close of $110.54.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $165.8 billion and is part of the health care sector. Shares are up 17.3% year-to-date as of the close of trading on Monday. Currently there are 13 analysts who rate Gilead a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Gilead

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Gilead Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).